The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis ; volume:23 ; number:1 ; day:15 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
Cardiovascular diabetology ; 23, Heft 1 (15.2.2024), 1-10, 12.2024
- Urheber
-
Ali, Muhammad Usman
Mancini, G. B. John
Fitzpatrick-Lewis, Donna
Connelly, Kim A.
O’Meara, Eileen
Zieroth, Shelley
Sherifali, Diana
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-024-02154-w
- URN
-
urn:nbn:de:101:1-2404230832523.639473625151
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ali, Muhammad Usman
- Mancini, G. B. John
- Fitzpatrick-Lewis, Donna
- Connelly, Kim A.
- O’Meara, Eileen
- Zieroth, Shelley
- Sherifali, Diana
- SpringerLink (Online service)
Ähnliche Objekte (12)
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes